Back to top

Analyst Blog

GlaxoSmithKline (GSK - Analyst Report) recently announced that it has reached an agreement with GlaxoSmithKline Consumer Nigeria plc regarding its proposal to increase its holding in the latter from 46.4% to 80%. Glaxo plans to increase its stake by acquiring shares on a pro rata basis. The offer, worth approximately £62 million, represents a premium of about 28% over the market price of the Nigerian subsidiary (closing price as on November 23, 2012 in the local stock exchange).

Glaxo Nigeria generated revenues of approximately NGN 21.5 billion in 2011 and demonstrated compound annual growth rate (CAGR) of 21% p.a. in the last 4 years.

On closure, subject to certain regulatory conditions, the deal will be immediately modestly accretive. Glaxo plans to fund the deal with its existing cash resources and remains on-track to buy back shares worth between £2 billion and £2.5 billion in 2012.

Meanwhile, Glaxo also announced its decision to increase its holding in its consumer healthcare subsidiary in India from 43.2% to up to 75%. The offer, worth approximately £591 million, represents a premium of about 28% over the market price of the Indian subsidiary (closing price as on November 23, 2012 in the local stock exchange).

Our Recommendation

We currently have a Neutral recommendation on Glaxo. The stock carries a Zacks #3 Rank (Hold rating) in the short run.

Several products in Glaxo's portfolio are facing declining sales due to intense generic competition. We expect the company's top line and gross margins to remain under pressure in the coming quarters. EU pricing pressure will also continue to affect sales.

Glaxo is aiming to maximize the potential return from its pipeline. The company is looking towards deals and acquisitions to drive growth. Further, the company is focusing on increasing the rights on its partnered products and promising pipeline candidates, so that it stands to benefit more from their success.

Glaxo's acquisition of Cellzome and Human Genome Sciences, increasing investment in Theravance Inc. (THRX - Analyst Report) and Amicus Therapeutics (FOLD - Snapshot Report) and amended agreement between ViiV Healthcare and Shionogi indicate its efforts to expand the pipeline.

Apart from this, Glaxo continues to progress on its cost-cutting initiative, which should help reduce the impact of increasing generic competition over the next few years and boost earnings.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%